Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$16.04 USD
-0.08 (-0.50%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $16.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Roivant Sciences Ltd.'s return on equity, or ROE, is -15.90% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that ROIV has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ROIV 16.04 -0.08(-0.50%)
Will ROIV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Is ROIV showing downside potential? MACD Bearish Signal Line Cross shows up after sinking 0.5%
ROIV rises 0.56% on October 9, leaving the technical picture intact
ROIV falls 0.56% on October 8, leaving the technical picture intact
Slingshot Bullish appears for ROIV after 0.86% move
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)